The global market for GLP-1 receptor agonists is witnessing a surge in demand due to their proven results in managing type 2 diabetes. Several pharmaceutical companies have earned FDA approval to develop these life-changing medications. {Novo Nordisk|Eli Lillyis a leading developer of GLP-1 receptor agonists, with well-established products like